PMID- 24018547 OWN - NLM STAT- MEDLINE DCOM- 20140915 LR - 20131107 IS - 1533-712X (Electronic) IS - 0271-0749 (Linking) VI - 33 IP - 6 DP - 2013 Dec TI - Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. PG - 806-9 LID - 10.1097/JCP.0b013e3182a412b8 [doi] AB - In recent years, lithium has proved an effective augmentation strategy of antidepressants in both acute and treatment-resistant depression. Neuroprotective and procognitive effects of lithium have been evidenced. Brain-derived neurotrophic factor (BDNF) has been shown to play a key role in the pathophysiology of several neurological and psychiatric disorders. The BDNF hypothesis of depression postulates that a loss of BDNF is directly involved in the pathophysiology of depression, and its restoration may underlie the therapeutic efficacy of antidepressant treatments. Brain-derived neurotrophic factor serum concentrations were measured in a total of 83 acutely depressed patients before and after 4 weeks of lithium augmentation. A significant BDNF increase has been found during treatment (F2,81 = 5.04, P < 0.05). Brain-derived neurotrophic factor concentrations at baseline correlated negatively with relative Hamilton Depression Scale change after treatment with lithium (n = 83; r = -0.23; P < 0.05). This is the first study showing that lithium augmentation of an antidepressant strategy can increase BDNF serum concentrations. Our study replicates previous findings showing that serum BDNF levels in patients with depressive episodes increase during effective antidepressant treatment. Further studies are needed to separate specific effects of different antidepressants on BDNF concentration and address potential BDNF downstream mechanisms. FAU - Ricken, Roland AU - Ricken R AD - From the *Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Mitte; daggerDepartment of Psychiatry and Psychotherapy, Schlossparkklinik; double daggerDepartment of Psychiatry and Psychotherapy, Vivantes Wenckebach Klinikum, Berlin, Germany; and section signDepartment of Psychiatry and Psychotherapy, University of Basel, Basel, Switzerland. FAU - Adli, Mazda AU - Adli M FAU - Lange, Claudia AU - Lange C FAU - Krusche, Esther AU - Krusche E FAU - Stamm, Thomas J AU - Stamm TJ FAU - Gaus, Sebastian AU - Gaus S FAU - Koehler, Stephan AU - Koehler S FAU - Nase, Sarah AU - Nase S FAU - Bschor, Tom AU - Bschor T FAU - Richter, Christoph AU - Richter C FAU - Steinacher, Bruno AU - Steinacher B FAU - Heinz, Andreas AU - Heinz A FAU - Rapp, Michael A AU - Rapp MA FAU - Borgwardt, Stefan AU - Borgwardt S FAU - Hellweg, Rainer AU - Hellweg R FAU - Lang, Undine E AU - Lang UE LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Psychopharmacol JT - Journal of clinical psychopharmacology JID - 8109496 RN - 0 (Antidepressive Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 2BMD2GNA4V (Lithium Carbonate) SB - IM MH - Acute Disease MH - Adult MH - Antidepressive Agents/administration & dosage/pharmacology/*therapeutic use MH - Brain-Derived Neurotrophic Factor/*blood MH - Depressive Disorder, Major/blood/*drug therapy/physiopathology MH - Depressive Disorder, Treatment-Resistant/blood/drug therapy/physiopathology MH - Drug Therapy, Combination MH - Female MH - Humans MH - Lithium Carbonate/administration & dosage/pharmacology/*therapeutic use MH - Male MH - Middle Aged MH - Psychiatric Status Rating Scales MH - Treatment Outcome EDAT- 2013/09/11 06:00 MHDA- 2014/09/16 06:00 CRDT- 2013/09/11 06:00 PHST- 2013/09/11 06:00 [entrez] PHST- 2013/09/11 06:00 [pubmed] PHST- 2014/09/16 06:00 [medline] AID - 10.1097/JCP.0b013e3182a412b8 [doi] PST - ppublish SO - J Clin Psychopharmacol. 2013 Dec;33(6):806-9. doi: 10.1097/JCP.0b013e3182a412b8.